参考文献
(在框内滑动手指即可浏览)
[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 朱云峰,陈晓飞.粪便隐血试验与SDC2基因甲基化检测在结直肠癌筛查中的效果评价[J].中国肿瘤,2022,31(9):5.
[3] 乐晨琴,刘成成,胡烨婷,等. 美国一般风险人群结直肠癌筛查指南更新解读[J]. 中华胃肠外科杂志,2022,25(9):826-833.
[4] 中国抗癌协会家族遗传性肿瘤专业委员会.中国家族遗传性肿瘤临床诊疗专家共识(2021 年版)(4)—家族遗传性结直肠癌[J].中国肿瘤临床,2022,49(1):1-5.
[5] Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group CSOCOC.Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J].Chin J Cancer Res,2019,31(1):117-134.
[6] Li J,Yuan Y,Yang F,et al.Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)[J].J Hematol Oncol,2019,12(1):16.
[7] Beets-Tan RGH,Lambregts DMJ,Maas M,et al.Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J].Eur Radiol,2018,28(4):1465-1475.
[8] Rouleau Fournier F,Motamedi MAK,Brown CJ,et al.Oncologic outcomes associated with MRI-detected extramural venous invasion (mrEMVI) in rectal cancer: A systematic review and Meta-analysis[J].Ann Surg,2022,275(2):303-314.
[9] Hoendervangers S,Burbach JPM,Lacle MM,et al.Pathological complete response following different neoadjuvant treatment strategies for locally advanced rectal cancer: A systematic review and Meta-analysis[J].Ann Surg Oncol,2020,27(11):4319-4336.
[10] Park SH,Cho SH,Choi SH,et al.MRI assessment of complete response to preoperative chemoradiation therapy for rectal cancer: 2020 guide for practice from the Korean society of abdominal radiology[J].Korean J Radiol,2020,21(7):812-828.
[11] Muaddi H,Silva S,Choi WJ,et al.When is a ghost really gone? A systematic review and meta-analysis of the accuracy of imaging modalities to predict complete pathological response of colorectal cancer liver metastases after chemotherapy[J].Ann Surg Oncol,2021,28(11):6805-6813.
[12] Tsili AC,Alexiou G,Naka C,et al.Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis[J].Acta Radiol,2021,62(3):302-312.
[13] O'Connell E,Galvin R,McNamara DA,et al.The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta-analysis[J].Colorectal Dis,2020,22(9):1076-1084.
[14] Liu W,Zhang ZY,Yin SS,et al.Contrast-enhanced intraoperative ultrasound improved sensitivity and positive predictive value in colorectal liver metastasis: a systematic review and meta-analysis[J].Ann Surg Oncol,2021,28(7):3763-3773.
[15] Mirshahvalad SA,Hinzpeter R,Kohan A,et al.Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2022,49(12):4205-4217.
[16] Steele SR,Chang GJ,Hendren S,et al.Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer[J].Dis Colon Rectum,2015,58(8):713-725.
[17] Blomqvist L,Holm T,Göranson H,et al.MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma[J].Acta Radiol,1996,37(5):779-784.
[18] Pema PJ,Bennett WF,Bova JG,et al.CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma[J].J Comput Assist Tomogr,1994,18(2):256-261.
[19] Schaefer O,Langer M.Detection of recurrent rectal cancer with CT, MRI and PET/CT[J].Eur Radiol,2007,17(8):2044-2054.
[20] Colosio A,Fornès P,Soyer P,et al.Local colorectal cancer recurrence: pelvic MRI evaluation[J].Abdominal imaging,2013,38(1):72-81.
[21] Guillem JG,Minsky BD.Extended perineal resection of distal rectal cancers: surgical advance, increased utilization of neoadjuvant therapies, proper patient selection or all of the above?[J].J Clin Oncol,2008,26(21):3481-3482.
[22] Kusters M,Marijnen CA,van de Velde CJ,et al.Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial[J].Eur J Surg Oncol,2010,36(5):470-476.
[23] Van Cutsem E,Nordlinger B,Cervantes A,et al.Advanced colorectal cancer: ESMO clinical practice guidelines for treatment[J].Ann Oncol,2010,21(suppl5):93-97.
[24] Kaur H,Choi H,You YN,et al.MR imaging for preoperative evaluation of primary rectal cancer: practical considerations[J].Radiographics,2012,32(2):389-409.
[25] Patel UB,Taylor F,Blomqvist L,et al.Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience[J].J Clin Oncol,2011,29(28):3753-3760.
[26] Battersby NJ,How P,Moran B,et al.Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: The MERCURY II study[J].Ann Surg,2016,263(4):751-760.
[27] Bamba Y,Itabashi M,Kameoka S.Preoperative evaluation of the depth of anal canal invasion in very low rectal cancer by magnetic resonance imaging and surgical indications for intersphincteric resection[J].Surg Today,2012,42(4):328-333.
[28] Shihab OC,How P,West N,et al.Can a novel MRI staging system for low rectal cancer aid surgical planning?[J].Dis Colon Rectum,2011,54(10):1260-1264.
[29] Fernandes MC,Gollub MJ,Brown G.The importance of MRI for rectal cancer evaluation[J].Surg Oncol,2022,43:101739.
[30] Shaukat A,Kaltenbach T,Dominitz JA,et al.Endoscopic recognition and management strategies for malignant colorectal polyps: Recommendations of the US multi-society task force on colorectal cancer[J].Gastroenterology,2020,159(5):1916-1934.
[31] Choi JY,Jung SA,Shim KN,et al.Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma[J].J Korean Med Sci,2015,30(4):398-406.
[32] Tanaka S,Kashida H,Saito Y,et al.Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection[J].Dig Endosc,2020,32(2):219-239.
[33] Matsuda T,Fukuzawa M,Uraoka T,et al.Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study[J].Cancer Sci,2011,102(9):1693-1697.
[34] Nagtegaal ID,Odze RD,Klimstra D,et al.The 2019 WHO classification of tumours of the digestive system[J].Histopathology,2020,76(2):182-188.
[35] Benson AB,Venook AP,Al-Hawary MM,et al.Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2022,20(10):1139-1167.
[36] Pimentel-Nunes P,Libânio D,Bastiaansen BAJ,et al.Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022[J].Endoscopy,2022,54(6):591-622.
[37] Lugli A,Kirsch R,Ajioka Y,et al.Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016[J].Mod Pathol,2017,30(9):1299-1311.
[38] Gress DM,Edge SB,Greene FL,et al.Principles of cancer staging [J].AJCC,2017(1):3-30.
[39] Martelli V,Pastorino A,Sobrero AF.Prognostic and predictive molecular biomarkers in advanced colorectal cancer[J].Pharmacol Ther,2022,236:108239.
[40] Wang J,Yi Y,Xiao Y,et al.Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS[J].Mod Pathol,2019,32(7):1053-1064.
[41] Sabiston,David C. Sabiston textbook of surgery[M]. 20 ed.Amsterdam: Elsevier,2016.
[42] 顾晋. 结直肠癌外科手术的切缘[J]. 中华胃肠外科杂志,2022,25(1):36-39.
[43] Heald RJ,Husband EM,Ryall RD.The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?[J].Br J Surg,1982,69(10):613-616.
[44] 关旭,王锡山. 结直肠肿瘤经自然腔道取标本手术的器官功能保护优势[J]. 中华胃肠外科杂志,2022,25(6):500-504.
[45] Yuan Z,Weng S,Ye C,et al.CSCO guidelines for colorectal cancer version 2022: Updates and discussions[J].Chin J Cancer Res,2022,34(2):67-70.
[46] Cercek A,Lumish M,Sinopoli J,et al.PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J].N Engl J Med,2022,386(25):2363-2376.
[47] Hu H,Kang L,Zhang J,et al.Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial[J].Lancet Gastroenterol Hepatol,2022,7(1):38-48.
[48] Grothey A,Sobrero AF,Shields AF,et al. Duration of adjuvant chemotherapy for stage Ⅲ colon cancer [J].N Engl J Med,2018,378(13):1177-1188.
[49] Li J,Qin S,Xu RH,et al.Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial[J].JAMA,2018,319(24):2486-2496.
[50] Xu RH,Muro K,Morita S,et al.Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J].Lancet Oncol,2018,19(5):660-671.
[51] André T,Shiu KK,Kim TW,et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J].N Engl J Med,2020,383(23):2207-2218.
[52] Li J,Deng Y,Zhang W,et al.Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J].J Hematol Oncol,2021,14(1):95.
[53] Hong DS,DuBois SG,Kummar S,et al.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials[J].Lancet Oncol,2020,21(4):531-540.
[54] Chen G,Peng J,Xiao Q,et al.Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer[J].J Hematol Oncol,2021,14(1):80.
[55] Tie J,Cohen JD,Lahouel K,et al.Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer[J].N Engl J Med,2022,386(24):2261-2272.
[56] Fakih MG,Kopetz S,Kuboki Y,et al.Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J].Lancet Oncol,2022,23(1):115-124.
[57] Kopetz S,Grothey A,Yaeger R,et al.Encorafenib, binimetinib, and cetuximab in <i>BRAF</i> V600E-mutated colorectal cancer[J].BRAF,2019,381(17):1632-1643.
[58] Strickler JH,Yoshino T,Graham RP,et al.Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review[J].JAMA Oncol,2022,8(5):760-769.
[59] Fokas E,Allgäuer M,Polat B,et al.Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12[J].J Clin Oncol,2019,37(34):3212-3222.
[60] Garcia-Aguilar J,Patil S,Gollub MJ,et al.Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy[J].J Clin Oncol,2022,40(23):2546-2556.
[61] Jin J,Tang Y,Hu C,et al.Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)[J].J Clin Oncol,2022,40(15):1681-1692.
[62] Bahadoer RR,Dijkstra EA,van Etten B,et al.Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J].Lancet Oncol,2021,22(1):29-42.
[63] Conroy T,Bosset JF,Etienne PL,et al.Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial[J].Lancet Oncol,2021,22(5):702-715.
[64] Bando H,Tsukada Y,Inamori K,et al.Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J].Clin Cancer Res,2022,28(6):1136-1146.
[65] Chalabi M,Fanchi LF,Dijkstra KK,et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J].Nat Med,2020,26(4):566-576.
[66] Lin Z,Cai M,Zhang P,et al.Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J].J Immunother Cancer,2021,9(11):e003554.
[67] Rahma OE,Yothers G,Hong TS,et al.Use of total neoadjuvant therapy for locally advanced rectal cancer: Initial results from the pembrolizumab arm of a phase 2 randomized clinical trial[J].JAMA Oncol,2021,7(8):1225-1230.
[68] Fernandez LM,São Julião GP,Figueiredo NL,et al.Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study[J].Lancet Oncol,2021,22(1):43-50.
[69] Fokas E,Appelt A,Glynne-Jones R,et al.International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer[J].Nat Rev Clin Oncol,2021,18(12):805-816.
[70] Peters FP,Teo MTW,Appelt AL,et al.Mesorectal radiotherapy for early stage rectal cancer: A novel target volume[J].Clin Transl Radiat Oncol,2020,21:104-111.
[71] Zhu J,Liu A,Sun X,et al.Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by <i>UGT1A1</i> status in patients with locally advanced rectal cancer[J].UGT1A1,2020,38(36):4231-4239.
[72] Garant A,Vasilevsky CA,Boutros M,et al.MORPHEUS phase II-III study: a pre-planned interim safety analysis and preliminary results[J].Cancers (Basel),2022,14(15):3665.
[73] Das P,Delclos ME,Skibber JM,et al.Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation[J].Int J Radiat Oncol Biol Phys,2010,77(1):60-65.
[74] Tao R,Tsai CJ,Jensen G,et al.Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity[J].Radiother Oncol,2017,122(1):146-151.